Abstract
Metabolic reprogramming in cancer cells is a strategy to meet high
proliferation rates, invasion, and metastasis. Also, several researchers indicated that the
cellular metabolism changed during the resistance to chemotherapy. Since glycolytic
enzymes play a prominent role in these alterations, the ability to reduce resistance to
chemotherapy drugs is promising for cancer patients. Oscillating gene expression of
these enzymes was involved in the proliferation, invasion, and metastasis of cancer
cells. This review discussed the roles of some glycolytic enzymes associated with
cancer progression and resistance to chemotherapy in the various cancer types.
[18]
Wolf A. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 2011; 208(2): 313-26.
[23]
Wang J. Knockdown of hexokinase 2 (HK2) inhibits breast cancer cell proliferation and reduces their resistance to fluorouracil. Xi bao yu fen zi Mian yi xue za zhi 2021; 37(8): 722-.
[65]
Liu H. The basic functions of phosphoglycerate kinase 1 and its roles in cancer and other diseases. Eur J Pharmacol 2022; 920: 174835.
[70]
He Y. PGK1-mediated cancer progression and drug resistance. Am J Cancer Res 2019; 9(11): 2280-302.
[85]
Zhu Q. Pyruvate kinase M2 inhibits the progression of bladder cancer by targeting MAKP pathway. J Cancer Res Ther 2018; 14: S616-21.
[86]
Chen J. MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma. Cell Prolif 2018; 51(6): e12510.